News | July 01, 2008

Clinicians Must Consider Economic Impact of New Interventions

July 2, 2008 - Cancer clinicians need to understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal for Clinicians, a peer-reviewed journal of the American Cancer Society, stating that healthcare budget constraints have made it necessary for clinicians to be aware of the relative costs and benefits of new interventions used in cancer screening, diagnosis, treatment and support services for patients.

The report highlights several examples of new interventions that may help specific populations but result in increased costs. They include magnetic resonance imaging screening for breast cancer, which at $1,000 per image is ten times the cost of screening mammography; $1,800 for a positron emission tomography (PET) scan for cancer staging; $48,000 per patient per year for the use of intensity-modulated radiation therapy to treat prostate cancer; $50,000 per patient per year for trastuzumab (Herceptin) in the treatment of HER-2-positive breast cancer; $1,800 per month for gefitinib (Iressa) for the treatment of lung cancer; and more than $8,000 for a six-day course of palifermin (Kepivance) in the treatment of oral mucositis.

The report reviews the methods used for economic analyses to help clinicians understand how economic evaluations of cancer interventions are performed so they are better able to use and critique these evaluations. The report states clinicians should care about economic analyses for several reasons: patients are increasingly required to pay for a proportion of their medical care; expenditures need to be prioritized to determine the most reasonable use of limited health care funds; and it is important that recommended medical treatments be "good buys."

The authors write, "unless clinicians, other cancer healthcare providers, and cancer researchers are active participants in discussions regarding the relative costs and benefits of new interventions, others will make these cost-effectiveness conclusions. Having members of the oncology community exclude themselves from these discussions and from the process of determining costs and benefits of new cancer therapies is unlikely to be in the best interests of cancer patients."

For more information: www.cancer.org

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
Russian Team Developing New Technology to Significantly Reduce MRI Research Costs
News | Magnetic Resonance Imaging (MRI) | January 16, 2018
January 16, 2018 — Researchers from the NUST MISIS Engineering Center for Industrial Technologies in Russia have deve
Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Emergency Radiologists See Inner Toll of Opioid Use Disorders

Rates of Imaging Positivity for IV-SUDs Complications. Image courtesy of Efren J. Flores, M.D.

News | Clinical Study | January 11, 2018
January 11, 2018 – Emergency radiologists are seeing a high prevalence of patients with complications related to opio
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Weight Loss Through Exercise Alone Does Not Protect Knees
News | Orthopedic Imaging | January 11, 2018
January 11, 2018 – Obese people who lose a substantial amount of weight can significantly slow down the degeneration
Neurofeedback Shows Promise in Treating Tinnitus

The standard approach to fMRI neurofeedback. Image courtesy of Matthew Sherwood, Ph.D.

News | Magnetic Resonance Imaging (MRI) | January 11, 2018
January 11, 2018 — Researchers using...
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
State-of-the-Art MRI Technology Bypasses Need for Biopsy
News | Magnetic Resonance Imaging (MRI) | January 09, 2018
January 9, 2018 – The most common type of tumor found in the kidney is generally quite small (less than 1.5 in).
Overlay Init